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trasted with the negative regulatory cells both express- of IL-2 and IL-15 cytokines and their receptors in the
balance between cytopathic and regulatory cells to yielding CD25 (IL-2R), was not anticipated. The sparing of
the negative regulatory cells from the ADCC process a rational approach for the treatment of autoimmune
diseases and for the maintenance of allograft retentionmay reflect the lower levels of expression of IL-2R on
these cells when contrasted with that of fully activated (Zheng et al., 2003; Guex-Crosier et al., 1997).
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approach being proposed by Zheng has successfully Zheng, X.X., Sa´nchez-Fueyo, A., Sho, M., Sayegh, M.H., and Strom,
T.B. (2003). Immunity, this issue, 503–514.translated the emerging insights concerning the roles
Currently only two transcriptional regulators, X boxIt’s a Good Year for Blimp-1
protein-1 (XBP-1) and B lymphocyte induced maturation(and Plasma Cells) protein 1 (Blimp-1), have been shown to be involved in
plasma cell differentiation. Chimeric mice whose lymphoid
system lacks XBP-1 have a severe impairment in the
production of immunoglobulin of all isotypes despite
Immunoglobulin secreting plasma cells are critical the presence of normal numbers of T and B cells. Inspec-
mediators of an effective humoral immune response. tion of the peripheral lymphoid tissue revealed an ab-
In this issue of Immunity, an article by Shapiro-Shelef sence of plasma cells, demonstrating an absolute re-
et al. defines an essential role for the transcription quirement for XBP-1 in B cell terminal differentiation
factor Blimp-1 in plasma cell differentiation and pre- (Reimold et al., 2001). Now an article by Shapiro-Shelef
plasma memory B cell formation. et al. in this issue of Immunity provides definitive proof
that Blimp-1 is also essential for plasmacytic differenti-
During a primary humoral response, engagement of anti- ation.
gen-specific receptors on naive B cells initiates a series Blimp-1 (also called PRD1), isolated by Mark Davis’
of temporally and spatially regulated events that lead to laboratory almost a decade ago, was the first transcrip-
the differentiation of both memory B cells and antibody- tion factor described to drive B cell differentiation to the
secreting plasma cells. As terminally differentiated ef- plasma cell stage (Turner et al., 1994). This zinc finger
fector cells, plasma cells play an essential role in the protein is specifically expressed in a subset of germinal
humoral immune response by producing large amounts center B cells and plasma cells. Overexpression of
of immunoglobulin (Ig). These antibodies act as protec- Blimp-1 in the BCL1 cell line induces plasmacytic differ-
tive effector molecules in the elimination of invading entiation accompanied by J chain expression and Ig
pathogens. Conversely, production of autoreactive anti- secretion (Calame, 2001). Unequivocal proof that Blimp-1
bodies is pathogenic in autoimmune diseases such as was required for plasma cell differentiation was missing,
systemic lupus erythematosus. Therefore a better un- however, because of the early embryonic lethality of
derstanding of the molecular mechanisms involved in homozygous mutant embryos. Shapiro-Shelef et al.
plasma cell differentiation and Ig secretion are crucial have now solved this problem. They generated mice
for effective drug design targeting autoimmune diseases lacking Blimp-1 in B cells by crossing mice expressing
CD19-driven Cre recombinase with mice in which theand vaccine development.
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prdm1 locus was flanked by loxP sites to generate con- 2001; Turner et al., 1994; Yoshida et al., 2001). The resul-
ditional null alleles of prdm1 in B cells. Although num- tant spliced XBP-1 mRNA encodes for a more transcrip-
bers and phenotype of bone marrow and splenic B cell tionally active form of XBP-1, and it is this spliced form
subsets appeared normal, serum Ig levels of all isotypes that has been specifically shown to be necessary for
were significantly reduced both at baseline and upon plasma cell differentiation and the UPR (Iwakoshi et al.,
immunization with T-independent and T-dependent an- 2003). It is still unclear whether XBP-1 has a distinct
tigens. As for XBP-1, both numbers of IgM secreting role in plasma cell differentiation in addition to its role
cells and CD138B220/– plasma cells were shown to in the UPR. Analogously, it is not clear whether Blimp-1
be significantly reduced. That the defect was intrinsic to is also involved in UPR-related secretory activities inde-
the B cell was evidenced by the failure of LPS stimulated pendent of XBP-1. The importance of the UPR in the
prdm1–/– B cells to produce wild-type levels of IgM and developmental program of plasma cells cell remains an
IgG3 and to differentiate into CD138 cells. intriguing question.
Recent microarray analyses have suggested that the The authors also examined memory B cell subsets in
mechanism by which Blimp-1 promotes plasma cell gen- prdm1/ mice and discovered that preplasma memory
eration largely relies on a program of transcriptional B cell formation is severely defective in the absence of
repression of genes involved in proliferation and germi- Blimp-1. Thus, immunized prdm1/ mice display a block
nal center function (Shaffer et al., 2002). Among the in the generation of antigen-specific B220– memory B
target genes identified were subsets of genes involved cells that results in the accumulation of an antigen-spe-
in cell cycle (c- myc, E2F-1, p18, and p21) and the inhibi- cific B220 cell population. This provocative result was
tion of apoptosis (A1). The hyperproliferation observed perhaps not entirely unexpected given that previous
in prdm1–/– B cells is consistent with a role for Blimp-1 work by this group provided evidence that a preplasma
as an inhibitor of cell division and ties in nicely with work B220– memory B cell population could rapidly differenti-
from Chen-Kiang on the cell cycle regulator p18 (INK4c) ate to CD138 plasma cells (McHeyzer-Williams et al.,
that revealed a close link between proliferation, apopto- 2000). A more precise, functional characterization of this
sis, and differentiation in generating the plasma cell lin- distinct B220 cell population that accumulates in the
eage (Morse et al., 1997). absence of Blimp-1 may be difficult since these cells
One interesting Blimp-1 target gene is XBP-1 itself. hyperproliferate and fail to produce antibody. Nonethe-
Previous work and data from this report showing defec- less, the involvement of Blimp-1 in memory B cell forma-
tive XBP-1 expression in Blimp-1/ B cells support the tion is an interesting observation that is certain to pro-
idea that Blimp-1 acts upstream of XBP-1. One way by vide new insights into a still poorly understood but
which Blimp-1 could induce XBP-1 transcription is by critical stage of humoral immunity.
relieving the repression by BSAP/Pax5, a B cell factor It wasn’t all that long ago when most discussions
that binds to and suppresses XBP-1 transcription. How- about plasma cell differentiation emphasized how little
ever, the lack of plasma cells in prdm1–/– B cells was not we knew about it. Although this is still true, some major
exclusively due to the absence of XBP-1, since ectopic strides have occurred in this field recently, as illustrated
expression of Blimp-1 but not XBP-1 restored plas- by the elegant paper by Shapiro-Shelef in this issue of
macytic differentiation. This is not surprising as the regu- Immunity. It confirms much of what we expected from
lation of XBP-1 is subject to complex transcriptional Blimp-1 but also offers novel insights and valuable tools
and posttranscriptional controls that likely stem from to pursue further studies in this arena.
additional upstream factors. For example, the immedi-
ate and early induction of XBP-1 by both IL-4 and IL-6
Neal N. Iwakoshi,1 Ann-Hwee Lee,1argues against a Blimp-1-dependent mechanism (Iwa-
and Laurie H. Glimcher1,2koshi et al., 2003). Thus, Blimp-1 and XBP-1 must control
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Harvard Medical Schoolpoorly understood in relation to Blimp-1 and XBP-1 and
Boston, Massachusetts 02115important goals for future studies. A comparison of
prdm1–/– and xbp-1–/– target genes should shed light on
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folding and transport of proteins from secretory cells Reimold, A.M., Iwakoshi, N.N., Manis, J., Vallabhajosyula, P., Szo-
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